Major clinical studies are not a case of enrolling a patient one day and announcing a cure the next. They involve incremental ...

Preclinical in vitro studies demonstrated >80% reduction in protease activity, including complete inhibition of TACE and collagenase — key factors in non-healing chronic wounds revyve® data featured ...

Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studies Icotrokinra also showed ...

Icotrokinra met the primary endpoint of clinical response at all three doses, with 36.5% of patients treated achieving endoscopic improvement and 30.2% achieving clinical remission at the highest dose ...

~ No serious adverse events and 92% reduction in seizure frequency observed in the first trial participant through first five months of follow up ~ ~ Data to be presented today at Epilepsy Therapies & ...

Dr. Alexander Spira explained the difference between a clinical trial and a real-world study in a CURE interview for patients with lung cancer. Real-world studies represent an important step in the ...

Xenon Pharmaceuticals provided an update on its pipeline programs, highlighting significant progress and upcoming milestones for 2025. The company anticipates topline data from its first Phase 3 study ...

SAN ANTONIO, September 26, 2025--bioAffinity Technologies shares 3 new case studies in which CyPath Lung detected Stage 1A lung cancer or prevented unnecessary invasive procedures.

This study is led by Professor Xin Sun (Institute of Integrated Traditional Chinese and Western Medicine and Chinese Evidence-based Medicine Center, Cochrane China and IDEAL China Center, West China ...

Chicago, IL - Just because a trial has been cited widely does not mean that its findings are accurate, new research has found [ 1]. In a paper in the July 13, 2005 issue of the Journal of the American ...